German biotech firm MorphoSys (FSE: MOR) and USA-based Celgene (Nasdaq: CELG), the world’s largest independent biotech company, have reached an agreement to jointly develop MOR202 globally and to co-promote MOR202 in Europe, in a multi-million dollar and equity deal.
The news sent MorphoSys' shares leaping 17% in morning trading, to 43.50 euros, their highest level since February 2001, according to Bloomberg.
MOR202 is currently being evaluated in a Phase I/IIa trial in patients with relapsed/refractory myeloma. MorphoSys and Celgene will collaborate on the development of MOR202 in multiple myeloma and other indications and share costs on a 1/3:2/3 basis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze